Mechanism Study on Inhibition of EPHA2 Expression Impaired Skin Barrier Function by Gefitinib

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Gefitinib (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) is effective for advanced Non-Small Cell Lung Cancer (NSCLC).
• Cutaneous toxicities from gefitinib limit its clinical use and impact patient outcomes.
• Understanding the mechanisms of gefitinib-induced dermal barrier dysfunction is crucial for developing new therapies.

Purpose of the Study:

• To identify etiological factors of gefitinib-induced dermal barrier dysfunction using network pharmacology and molecular docking.
• To investigate the role of Ephrin Type-A Receptor 2 (EPHA2) in gefitinib-induced skin toxicity.
• To explore potential therapeutic strategies targeting EPHA2.

Main Methods:

• Network pharmacology and molecular docking to identify key mediators.
• Murine models and HaCaT keratinocytes to assess gefitinib's effects.
• Hematoxylin and Eosin (HE) staining, immunohistochemistry, RT-qPCR, and Western Blot assays to evaluate molecular changes.
• Administration of an EPHA2 agonist (Ephrin-A1 Fc) to test therapeutic potential.

Main Results:

• Network pharmacology and molecular docking identified EPHA2 as a central mediator.
• Gefitinib induced skin damage in mice and altered keratin and desmoglein expression in keratinocytes.
• Gefitinib suppressed EPHA2 expression and keratinocyte viability while increasing inflammatory markers.
• Ephrin-A1 Fc treatment ameliorated gefitinib-induced skin damage and reversed molecular changes.

Conclusions:

• Gefitinib induces dermal barrier dysfunction primarily through the downregulation of EPHA2.
• Restoring EPHA2 expression or activity may represent a viable therapeutic strategy to mitigate gefitinib-induced cutaneous toxicities.
• This research provides insights into the mechanisms of EGFR-TKI-related skin adverse events.